Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AK139 injection in chronic rhinosinusitis with nasal polyps
CTR20262926Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Akeso, Inc.. Started Aug 2026; status: active.
02
Drugs
AK139
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20262926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262926.